Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi

 Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation

Nurix anticipates nominating a clinical candidate within the first year of the extension

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced today an extension of the ongoing research program with Sanofi US for STAT6 (signal transducer and activator of transcription 6). STAT6 is a key drug target in type 2 inflammation.

https://www.biospace.com/article/releases/nurix-therapeutics-announces-extension-of-strategic-collaboration-with-sanofi-to-develop-novel-targeted-protein-degraders-of-stat6/